Phase Ia/Ib Study of RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors

RS Arastirma

Status and phase

Enrolling

Phase 1

Conditions

Solid Tumors

Treatments

Drug: RS-0139

Study type

Interventional

Funder types

Industry

Identifiers

NCT04261413

RS-001

Details and patient eligibility

About

This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors. The research is planned as a two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.

Enrollment

16 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have consented to participation in the trial.
Patients of both sexes aged between 18 and 75 years.
Patients with relapsed or refractory solid tumors who have failed available standard therapy or are not candidates for standard therapy.
Patients who are willing to provide fresh or archival biopsy material before their participation to identify the integrin expression levels (for Phase Ib only).
Patients who completed the previous treatments 21 days before the first dose of the study drug.
Patients who have at least three months of life expectancy.
Patients with ECOG performance score 0 to 1.
Patients with adequate organ function defined as:
- Hemoglobin ≥10 mg/dl
- Neutrophil ≥1,500/µL
- Platelet ≥100,000/µL
- Creatinine ≤1.5xULN or creatinine clearance ≥60mL/sec/1.73m2
- Total bilirubin ≤ 1.5xULN
- AST/ALT ≤2.5xULN; for patients who have confirmed liver metastasis: AST/ALT ≤5xULN.
- Prothrombin time ≤1.5xULN (in case of no anticoagulant treatment).
- Normal levels of serum magnesium and potassium concentrations

Exclusion criteria

Patients with active and/or uncontrolled central nervous system (CNS) metastasis.
Patients who have interstitial lung disease or interstitial pneumonia.
Patients who have serious cardiac dysfunction.
Patients who have insufficient target organ function.
Patients with positive tests for HAV, HBV, HCV or HIV.
Patients who experienced grade 3 or higher toxicity related to the previous docetaxel treatment.
Female patients who are pregnant or breastfeeding.
Male patients with pregnant female partners.
Patients enrolled in another clinical trial at the same time or recently completed an investigational drug study and received the last dose of an investigational drug within 30 days or five half-lives (whichever is longer).
Patients who have serious medical conditions such as uncontrolled infection or untreated wounds.
Patients who have bone marrow transplantation history.
Patients who have hypersensitivity to docetaxel, components of RS-0139 and/or other taxanes.
Patients taking inhibitors or inducers of CYP3A4, including grapefruit juice and OTC medications such as St. John's Wort.
Patients who, in the judgment of the PI, are likely to be non-compliant or unable to cooperate.
Patients who cannot be contacted in case of emergency.
Patients who are the PI or sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conducting the study.